Panacea Biotec Limited (NSE:PANACEABIO)
360.25
-22.70 (-5.93%)
Jan 21, 2026, 3:29 PM IST
Panacea Biotec Revenue
Panacea Biotec had revenue of 1.41B INR in the quarter ending September 30, 2025, a decrease of -4.22%. This brings the company's revenue in the last twelve months to 6.04B, up 9.79% year-over-year. In the fiscal year ending March 31, 2025, Panacea Biotec had annual revenue of 5.59B, down -0.01%.
Revenue (ttm)
6.04B
Revenue Growth
+9.79%
P/S Ratio
3.66
Revenue / Employee
2.81M
Employees
2,149
Market Cap
22.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.59B | -740.00K | -0.01% |
| Mar 31, 2024 | 5.59B | 992.22M | 21.57% |
| Mar 31, 2023 | 4.60B | -2.01B | -30.44% |
| Mar 31, 2022 | 6.61B | 364.27M | 5.83% |
| Mar 31, 2021 | 6.25B | 807.43M | 14.84% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 164.76B |
| Dishman Carbogen Amcis | 27.59B |
| Anthem Biosciences | 20.77B |
| OneSource Specialty Pharma | 15.22B |
| Blue Jet Healthcare | 11.79B |
| Concord Biotech | 11.25B |
| Supriya Lifescience | 7.15B |
| Zota Health Care | 4.02B |
Panacea Biotec News
- 13 days ago - Panacea Biotec shares jump over 4% after completion of Dengue vaccine Phase III trial enrolment - Business Upturn
- 2 months ago - Panacea Biotec CFO Devender Gupta resigns; last working day December 15 - Business Upturn
- 3 months ago - Panacea Biotec secures Rs 127.2 crore order from Government of India for supply of bivalent oral polio vaccine - Business Upturn
- 3 months ago - Panacea Biotec shares rally sharply over 4% after securing contract worth Rs 315 crore from UNICEF - Business Upturn
- 3 months ago - Panacea Biotec bags order worth Rs 315 crore for supply of oral polio vaccine from UNICEF - Business Upturn
- 4 months ago - Top stocks to buy today: Stock recommendations for September 17, 2025 - check list - The Times of India
- 8 months ago - Panacea Biotec’s EmulsiPan listed in CEPI Adjuvant Library to support vaccine development - Business Upturn
- 9 months ago - Panacea Biotec shares hit 5% upper circuit after additional UNICEF vaccine order worth Rs 44 crore - Business Upturn